Previous 10 | Next 10 |
2023-11-21 10:11:25 ET Summary Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company is expected to grow EBITDA significantly in the coming years through its existing business and potential acquisi...
2023-11-13 11:08:06 ET Kamada Ltd. (KMDA) Q3 2023 Earnings Conference Call November 13, 2023, 08:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call ...
2023-11-13 07:11:10 ET More on Kamada The AAT Caveat In Kamada's Upbeat Quarter Kamada reports shareholder approval and planned closing of $60M private placement with FIMI opportunity funds Seeking Alpha’s Quant Rating on Kamada For further details see...
Third Quarter 2023 Revenues were $37.9 Million Representing a n 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-Year Third Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% Increase Year-over-Year; ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Kamada Ltd. (KMDA) is expected to report $0.03 for Q3 2023
2023-11-10 12:17:28 ET More on Kamada The AAT Caveat In Kamada's Upbeat Quarter Kamada Ltd. (KMDA) Q2 2023 Earnings Call Transcript Kamada reports shareholder approval and planned closing of $60M private placement with FIMI opportunity funds Kamada beats Q2 t...
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, toda...
Following Recent FDA Approval of Technology Transfer Process, CYTOGAM ® Manufactured by Kamada at its Facility Now Available for Commercial Sales in U.S. New Clinical Data Highlighting Five -year Real-world Survival Benefits of High Risk ...
2023-10-10 07:49:22 ET More on Kamada The AAT Caveat In Kamada's Upbeat Quarter Kamada reports shareholder approval and planned closing of $60M private placement with FIMI opportunity funds Kamada beats Q2 top and bottom line estimates; reaffirms FY23 outlook ...
News, Short Squeeze, Breakout and More Instantly...
Kamada Ltd. Company Name:
KMDA Stock Symbol:
NASDAQ Market:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Revenues for First Quarter of 2024 were $37.7 Million, Representing a 23% Increase Year-over-Year First Quarter 2024 Adjusted EBITDA of $7.5 Million, Representing a 96% Increase Year-over-Year Momentum Primarily Driven by U.S. Sales of the Company’s Two Most Significant Cat...